On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked
On May 8th, Johnson & Johnson announced that Darzalex (daratumumab) new indication has received FDA approval for the combined use of bortezomib, melphalan and prednisone for first-line treatment of newly diagnosed unfit autologous stem cell transplantation (ASCT) multiple myeloma patient. In this way, Darzalex began with the FDA approval in… Continue Reading Johnson’s blockbuster Darzalex has been upgraded to receive first-line treatment for multiple myeloma.
IDO Inhibitor Stops Recruiting Patients in Multiple Clinical Trials On May 2, Incyte announced that multiple late-stage clinical trials of epacadostat with MSD, Bristol-Myers Squibb, and Aslicon PD-1/PD-L1 drugs will stop the recruitment of patients. At the same time, Bristol-Myers Squibb also stopped several clinical trials with the PD-1 combination… Continue Reading A week of news